Discover how semaglutide may reduce the risk of kidney failure and heart complications in individuals with type 2 diabetes and chronic kidney disease.
Type 2 diabetes and chronic kidney disease (CKD) are two intertwined health challenges affecting millions worldwide. For patients grappling with both conditions, the risks of kidney failure, cardiovascular events, and mortality are significantly heightened. While previous articles provided strong evidence of Ozempic being useful in CKD, a large-scale confirmation from 1000s of individuals across many countries confirmed the benefits of the prestigious NEJM. The proof that Semaglutide is beneficial for CKD is considered to be on par with the evidence for sugar control, weight control, and cardiovascular outcomes. Ozempic may also be helpful for nicotine addiction, for example, but the level of certainty is yet to be confirmed by large-scale clinical trials.
Understanding Type 2 Diabetes and Chronic Kidney Disease
- Type 2 Diabetes: A chronic condition where the body struggles to regulate blood sugar levels due to insulin resistance or insufficient insulin production. High blood sugar can damage various organs over time.
- Chronic Kidney Disease: A gradual loss of kidney function over time. Kidneys filter waste and excess fluids from the blood; when they’re damaged, harmful levels of fluid and waste can accumulate.
Diabetes is a leading cause of CKD. High blood sugar can damage blood vessels in the kidneys, impairing their ability to function properly. Managing both conditions effectively is crucial to prevent serious complications like kidney failure and cardiovascular disease.
What Is Semaglutide?
Semaglutide is a medication belonging to a class called glucagon-like peptide-1 (GLP-1) receptor agonists. It’s primarily used to improve blood sugar control in adults with type 2 diabetes. Semaglutide works by mimicking a natural hormone that stimulates insulin secretion, inhibits glucagon release, slows gastric emptying, and reduces appetite.
The Study at a Glance
A recent international, double-blind, randomized controlled trial investigated the effects of semaglutide on patients with type 2 diabetes and CKD. Here’s what you need to know:
- Participants: 3,533 adults with type 2 diabetes and CKD.
- Duration: Median follow-up period of 3.4 years.
- Treatment: Participants were randomly assigned to receive either semaglutide (1.0 mg once weekly via subcutaneous injection) or a placebo.
- Objective: To determine whether semaglutide could reduce the risk of major kidney events, such as kidney failure or significant loss of kidney function, and death from kidney-related or cardiovascular causes.
Key Findings
- Reduction in Major Kidney Events:
- Risk Reduction: Semaglutide reduced the risk of major kidney events by 24% compared to placebo.
- What This Means: For every 20 patients treated with semaglutide over three years, one major kidney event could be prevented.
- Slower Decline in Kidney Function:
- eGFR Slope: The estimated glomerular filtration rate (eGFR), a measure of kidney function, declined more slowly in the semaglutide group.
- Annual Decline:
- Semaglutide group: 2.19 ml/min/1.73 m² per year.
- Placebo group: 3.36 ml/min/1.73 m² per year.
- Interpretation: Semaglutide slowed the rate of kidney function decline by approximately 1.16 ml/min/1.73 m² per year.
- Reduction in Cardiovascular Deaths:
- Risk Reduction: There was a 29% reduction in the risk of death from cardiovascular causes in the semaglutide group.
- Implication: Semaglutide not only benefits kidney health but also significantly lowers heart-related mortality.
- Lower All-Cause Mortality:
- Risk Reduction: Death from any cause was reduced by 20% in patients receiving semaglutide.
- Practical Outcome: Treating 39 patients with semaglutide over three years could prevent one death. This means the Number Needed to Treat ( NNT) is 39. A lower number is better.
- Improved Blood Sugar Control and Weight Loss:
- Glycated Hemoglobin (HbA1c): Semaglutide led to greater reductions in HbA1c levels, indicating better blood sugar control.
- Weight Loss: Patients on semaglutide lost an average of 4.10 kg (about 9 lbs) more than those on placebo over two years.
Understanding the Numbers
- Hazard Ratio (HR): A statistical measure used to compare the risk of an event occurring between two groups. An HR less than 1 indicates a reduction in risk with treatment.
- For Major Kidney Events: HR of 0.76 means there’s a 24% reduction in risk with semaglutide.
- Number Needed to Treat (NNT): The number of patients who need to be treated to prevent one additional bad outcome.
- For Major Kidney Events: NNT of 20 over three years.
- For All-Cause Mortality: NNT of 39 over three years.
Safety and Side Effects
While semaglutide showed significant benefits, some patients experienced side effects:
- Gastrointestinal Issues: Nausea, vomiting, or diarrhea were more common and led to discontinuation in some cases.
- Eye Disorders: Slightly higher incidence of serious eye disorders (e.g., diabetic retinopathy) in the semaglutide group, though the overall rates were similar between groups.
Overall, semaglutide was well-tolerated, and serious adverse events were less frequent compared to placebo.
Implications for Patients
The study’s results are promising for patients with type 2 diabetes and CKD:
- Kidney Health: Semaglutide may become a valuable tool in slowing CKD progression, potentially delaying the need for dialysis or transplantation.
- Cardiovascular Benefits: The medication may reduce the risk of heart attacks, strokes, and cardiovascular deaths.
Next Steps
If you or a loved one is managing type 2 diabetes and CKD, consider discussing semaglutide with your healthcare provider. They can evaluate whether this medication is appropriate for your treatment plan. Remembering certain factors may make an individual a less-than-ideal candidate for a particular medication is essential.
Disclaimer: This article is for informational purposes only and does not substitute professional medical advice. Always consult a qualified healthcare provider for guidance tailored to your health situation.
At CanadianInsulin.com, we’re dedicated to providing up-to-date information and quality medications to support your health needs. Explore our range of GLP-1 receptor agonists and consult with our pharmacists for more information.
